IMB Developed Biotechmycin through Genetic Engineering    

The Institute of Medicinal Biotechnology of Chinese Academy of Medical Sciences (IMB) announced on January 7th that it has completed the III phase clinical trails for biotechmycin it invented. Biotechmycin is a new member of macrolides antibiotic family and China's A-grade candidate substance for chemical new drug. IMB won three patents by this invention.    
   Wang Yiguang, professor of IMB, said that biotechmycin is the first candidate substance for chemical new drug worldwide that is made by genetic technology. Clinical trails results illustrated that biotechmycin has good therapeutic effects and safety.
   Presently, most antibiotic medicines are chemically synthesized, often causing pollution. Genetic engineering technology can solve the pollution problem well.
    Jiang Jiandong, director of IMB, pointed out that the invention of biotechmycin marked that China has primarily built a set of practice technologies to manufacture hybrid antibiotic series chemical drugs from composed biological synthesis genetic engineering bacteria.